Hypoaldosteronism overview

Jump to navigation Jump to search

Hypoaldosteronism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypoaldosteronism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypoaldosteronism overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypoaldosteronism overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypoaldosteronism overview

CDC on Hypoaldosteronism overview

Hypoaldosteronism overview in the news

Blogs on Hypoaldosteronism overview

Directions to Hospitals Treating Hypoaldosteronism

Risk calculators and risk factors for Hypoaldosteronism overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

Hypoaldosteronism is defined as decreased levels of the hormone aldosterone or a resistance of the target tissue to the actions of aldosterone. There are several causes for decreased levels of aldosterone, including kidney disorders, adrenal insufficiency, congenital adrenal hyperplasia, and medications such as ACE inhibitors, angiotensin receptor blockers, NSAIDs and calcineurin inhibitors. Mutation in the mineralocorticoid receptor gene (NR3C2) may lead to resistance to the actions of the aldosterone. Hypoaldosteronism results in hyperkalemia, which can be a serious medical condition. Hyponatremia is unusual in isolated aldosterone deficiency as under normal conditions cortisol inhibits antidiuretic hormone secretion. In patients with adrenal insufficiency as a cause of hypoaldosteronism, decrease in cortisol, aldosterone, and androgen levels may lead to hyponatremia. Hypoaldosteronism may be classified into two categories depending on the level of plasma renin and depending on the level of aldosterone. The most common cause of hypoaldosteronism is diabetic nephropathy, acute glomerulonephritis, tuberculosis, hemorrhage, infarction, sarcoidosis, AIDS, CMV, and Addison's disease. Less common causes of hypoaldosteronism include sarcoidosis, amyloidosis, fungal infections, AIDS complications, and hemochromatosis.Hypoaldosteronism must be differentiated from other diseases that cause hypotension and muscle weakness. Common risk factors in the development of hypoaldosteronism include diabetes mellitus, sickle cell anemia, HIV, graves' disease, hypoparathyroidism, hypopituitarism, myasthenia gravis, and pernicious anemia. If left untreated, hypoaldosteronism may lead to hyperkalemia and severe muscle weakness. Common complications of hypoaldosteronism include hyperkalemia, metabolic acidosis, hypotension, hypovolemia and hyponatremia. Prognosis of hypoaldosteronism is generally good for patients who receive treatment.

Historical Perspective

Hypoaldosteronism was first described by an American physician Hudson JB in the year 1956. Later on, in the year 1964, physicians Viser and Ulick gave a description on isolated and congenital hypoaldosteronism respectively.

Classification

Hypoaldosteronism may be classified on the basis of plasma renin levels into hyporeninemic hypoaldosteronism and hyperreninemic hypoaldosteronism. Hypoaldosteronism can also be classified on the basis of plasma aldosterone levels into aldosterone deficiency and aldosterone resistance.

Pathophysiology

Hypoaldosteronism is defined as decreased levels of the hormone aldosterone or a resistance of the target tissue to the actions of aldosterone. Hypoaldosteronism from decreased production is seen in conditions such as congenital isolated hypoaldosteronism, primary adrenal insufficiency, diabetic nephropathy, critical illness, and drugs such as ACE inhibitors, NSAIDs and calcineurin inhibitors. Resistance of the target tissue to the actions of aldosterone is seen with mineralocorticoid receptor defects (seen in pseudohypoaldosteronism) and with drugs such as potassium-sparing diuretics and trimethoprim. Hypoaldosteronism results in reduced reabsorption of sodium in the principal cells of cortical collecting tubules (CCT). This leads to decreased excretion of potassium (hyperkalemia) and mild non-anion gap metabolic acidosis. On gross pathology, adrenal glands may be irregularly shrunken or hyperplastic.

Causes

The common causes of hypoaldosteronism include diabetic nephropathy, acute glomerulonephritis, tuberculosis, hemorrhage, infarction, sarcoidosis, AIDS, CMV infection, and Addison's disease. Less common causes of hypoaldosteronism include sarcoidosis, amyloidosis, fungal infections, AIDS complications, and hemochromatosis.

Differentiating Hypoaldosteronism from Other Diseases

Hypoaldosteronism must be differentiated from other diseases that cause hypotension and muscle weakness such as Addison's disease, myopathies, celiac disease, Peutz-Jeghers syndrome, anorexia nervosa, syndrome of inappropriate anti-diuretic hormone (SIADH), neurofibromatosis, porphyria cutanea tarda, salt-depletion nephritis and bronchogenic carcinoma. In addition, measurement of plasma renin activity (PRA), serum aldosterone, and serum cortisol is used to differentiate among various subtypes of hypoaldosteronism.

Epidemiology and Demographics

In hospitalized patients, the incidence of hypoaldosteronism is 3000 per 100,000 individuals. The prevalence of hypoaldosteronism in United states is estimated to be 200,000 cases. Hypoaldosteronism is most commonly seen in middle-aged and older individuals. Both men and women are affected equally. Hypoaldosteronism is more prevalent in African-American, Native Americans, and Hispanics.

Risk Factors

Common risk factors in the development of hypoaldosteronism include diabetes mellitus, sickle cell anemia, HIV, graves' disease, hypoparathyroidism, hypopituitarism myasthenia gravis, and pernicious anemia. Other less common risk factors include multiple myeloma, SLE-associated renal disease and Wolmans disease.

Screening

There is insufficient evidence to recommend routine screening for hypoaldosteronism.

Natural History, Complications, and Prognosis

If left untreated, hypoaldosteronism leads to hyperkalemia which can alter the function of cardiac conduction pathways. Depending upon the severity of hypoaldosteronism, hyperkalemia can be a life threatening condition. When serum potassium rises above ≥ 9 mEq/L, hyperkalemia may lead to ventricular fibrillation, PEA and even cardiac arrest. Common complications of hypoaldosteronism include hyperkalemia, metabolic acidosis, hypotension, hypovolemia and hyponatremia. Depending on the extent of the hyperkalemia and underlying renal or adrenal condition at the time of diagnosis, the prognosis of hypoaldosteronism may vary. Prognosis of hypoaldosteronism is generally good for patients who receive treatment.

Diagnosis

Diagnostic Criteria

There is no established criteria for the diagnosis of hypoaldosteronism. However, a positive history of hypotension, muscle weakness and fatigue should raise suspicion for hypoaldosteronism. These patients should first be tested for serum potassium levels, plasma renin activity (PRA), serum aldosterone, and serum cortisol. Asymptomatic hypoaldosteronism can also be discovered on routine laboratory evaluations.

History and Symptoms

Hypoaldosteronism often has a gradual onset. Patients of hypoaldosteronism should be enquired about the use of drugs that can alter aldosterone production or function. These drugs include ACE inhibitors, angiotensin receptor blockers and NSAIDs. The most common symptoms of hypoaldosteronism include fatigue, muscle weakness, and low blood pressure. Other less common symptoms of hypoaldosteronism include hyperpigmentation, gastrointestinal disturbances, and abdominal pain.

Physical Examination

Patients with hypoaldosteronism usually appear fatigued. Physical examination of patients with hypoaldosteronism is usually unremarkable, unless there is severe hyperkalemia. Increased level of serum potassium level may present with muscle tenderness, hyporeflexia/areflexia and cardiac arrhythmias. The physical exam may also represent findings of underlying condition such as chronic kidney disease or diabetic nephropathy.

Laboratory Findings

Laboratory findings consistent with the diagnosis of hypoaldosteronism include hyperkalemia and mild non-anion gap metabolic acidosis. Other lab findings include hyponatremia, decreased aldosterone level, and variable amounts of plasma renin activity (depends upon the underlying condition).

Electrocardiogram

In hypoaldosteronism there are no specific ECG findings. However, hypoaldosteronism predisposes to hyperkalemia (decreased renal excretion) and occasional hyponatremia (from decreased renal absorption). Hyperkalemia leads to depression of SA node and conduction pathways such as AV node and His-Purkinje system causing bradycardia and conduction blocks. On the other hand, severe hyponatremia may present with ST segment elevation mimicking acute myocardial infarction.

X-ray

There are no x-ray findings associated with hypoaldosteronism.

Ultrasound

There are no specific findings of hypoaldosteronism on ultrasound. However, ultrasound may be helpful in the diagnosis of hypoaldosteronism from disorders of renal or adrenal glands. Chronic kidney disease is an important cause of hypoaldosteronism and on ultrasound presents with reduced renal length, reduced renal cortical thickness, and with poor visibility of the renal pyramids and the renal sinus. Hypoaldosteronism from adrenal insufficiency may present with irregularly shrunken adrenal glands, adrenal nodules, and signs of calcium deposits.

CT scan

There are no CT scan findings associated with hypoaldosteronism. A CT scan is not routinely done for the diagnosis of hypoaldosteronism.

MRI

There are no specific MRI findings associated with hypoaldosteronism.

Other Imaging Findings

There are no other imaging findings associated with hypoaldosteronism.

Other Diagnostic Studies

There are no other diagnostic studies associated with hypoaldosteronism.

Treatment

Medical Therapy

The mainstay of treatment for hypoaldosteronism depends upon the level of plasma potassium. Prompt ECG is advised in all patients suspected of hypoaldosteronism as hyperkalemia may lead to cardiac conduction defects and life threatening arrhythmias. Patients with no ECG changes and moderate hyperkalemia (6.5–7.5 mmol/l) require only monitoring. Patients with severe hyperkalemia (>7.5 mmol/l) are treated with emergency measures for hyperkalemia (calcium, insulin, β2 agonist or cation resins) and fludrocortisone. Depending upon the volume status, patients may be treated with either 0.9% normal saline (hypovolemia) or furosemide (hypervolemic).

Surgery

Surgical intervention is not recommended for the management of hypoaldosteronism.

Primary Prevention

There are no established measures for the primary prevention of hypoaldosteronism.

Secondary Prevention

Effective measures for the secondary prevention of hypoaldosteronism include liberal salt intake of 4gm/day (to increase plasma sodium concentration), decreasing potassium intake and avoidance of drugs that affects renin angiotensin aldosterone system (RAAS) such as ACE inhibitors, ARBs, potassium sparing diuretics and β-Adrenergic receptor blockers.

References


Template:WikiDoc Sources